Successful Treatment of Afatinib-Refractory Non-Small Cell Lung Cancer with Uncommon Complex EGFR Mutations Using Pembrolizumab: A Case Report

Successful Treatment of Afatinib-Refractory Non-Small Cell Lung Cancer with Uncommon Complex EGFR Mutations Using Pembrolizumab: A Case Report

Although there has been significant progress in immune-checkpoint inhibitor (ICI) treatment, it remains controversial whether they should be used in the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). We herein report the case of an NSCLC patient with...

Full description

Bibliographic Details
Main Authors: Yuri Taniguchi, Momoko Yamamoto, Hiroaki Ikushima, Sayaka Ohara, Hideyuki Takeshima, Toshio Sakatani, Kazuhiro Usui
Format: Article
Language:English
Published: Karger Publishers 2019-07-01
Series:Case Reports in Oncology
Subjects:
Afatinib
EGFR uncommon mutation
Immune-checkpoint inhibitor
Non-small-cell lung cancer
Pembrolizumab
Online Access:https://www.karger.com/Article/FullText/501848

Internet

https://www.karger.com/Article/FullText/501848

Similar Items